SCHEMBL4597996

SCHEMBL4597996

O=C(NCC(F)(F)F)C1c2ccccc2-c2ccccc21

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.56
HDAC4 P56524 1/20 0.56
HDAC7 Q8WUI4 1/20 0.56
HDAC8 Q9BY41 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
HDAC9 Q9UKV0 1/20 0.56
HDAC5 Q9UQL6 1/20 0.56
NCOR2 Q9Y618 1/20 0.56
POLB P06746 2/20 0.54
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44
DRD3 P35462 1/20 0.44
PSEN1 P49768 1/20 0.44
PSEN2 P49810 1/20 0.44
APH1B Q8WW43 1/20 0.44
NCSTN Q92542 1/20 0.44
APH1A Q96BI3 1/20 0.44
PSENEN Q9NZ42 1/20 0.44
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8135854 0.87 HDAC3 (0.53) HDAC3HDAC4HDAC7HDAC8HDAC6
SCHEMBL8135190 0.84 POLB (0.50) HDAC3HDAC4HDAC7HDAC8HDAC6
SCHEMBL8483124 0.84 POLB (0.45) HDAC3HDAC4HDAC7HDAC8HDAC6
SCHEMBL8577606 0.81 POLB (0.42) HDAC3HDAC4HDAC7HDAC8HDAC6
SCHEMBL8126858 0.80 APOL1 (0.38) POLB
SCHEMBL8673587 0.79 POLB (0.41) HDAC3HDAC4HDAC7HDAC8HDAC6
SCHEMBL17729935 0.78 POLB (0.38) HDAC3HDAC4HDAC7HDAC8HDAC6
SCHEMBL6713006 0.76 POLB (0.39) HDAC3HDAC4HDAC7HDAC8HDAC6
SCHEMBL7716498 0.76 PSEN1 (0.41) HDAC3HDAC4HDAC7HDAC8HDAC6
SCHEMBL9398200 0.76 HDAC3 (0.59) HDAC3HDAC4HDAC7HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0904262-A4 CONFORMATIONALLY RESTRICTED AROMATIC INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD BRISTOL MYERS SQUIBB CO (US) 2000-10-04 EP claimed
EP-0904262-A1 CONFORMATIONALLY RESTRICTED AROMATIC INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 1999-03-31 EP claimed
WO-1997026240-A1 CONFORMATIONALLY RESTRICTED AROMATIC INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 1997-07-24 WO claimed
US-10934251-B2 Process for the preparation of lomitapide HETERO RESEARCH FOUNDATION (IN) 2021-03-02 US disclosed
US-10934251-B2 Process for the preparation of lomitapide HETERO RESEARCH FOUNDATION (IN) 2021-03-02 US disclosed
US-20200190018-A1 Process For The Preparation of Lomitapide HETERO RESEARCH FOUNDATION (IN) 2020-06-18 US disclosed
US-20200190018-A1 Process For The Preparation of Lomitapide HETERO RESEARCH FOUNDATION (IN) 2020-06-18 US disclosed
US-20180291773-A1 PROCESS FOR THE PREPARATION OF LOMITAPIDE HETERO RESEARCH FOUNDATION (IN) 2018-10-11 US disclosed
US-10023526-B2 Process for the preparation of lomitapide HETERO RESEARCH FOUNDATION 2018-07-17 US disclosed
US-10023526-B2 Process for the preparation of lomitapide HETERO RESEARCH FOUNDATION 2018-07-17 US disclosed
US-10023526-B2 Process for the preparation of lomitapide HETERO RESEARCH FOUNDATION 2018-07-17 US disclosed
WO-2006124713-A2 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES MICROBIA, INC. (US) 2006-11-23 WO disclosed
WO-2006122186-A2 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA MICROBIA, INC. (US) 2006-11-16 WO disclosed
WO-2006121861-A2 BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS MICROBIA, INC. (US) 2006-11-16 WO disclosed
WO-2006116499-A1 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA MICROBIA, INC. (US) 2006-11-02 WO disclosed
WO-2006086562-A2 PHENYLAZETIDINONE DERIVATIVES MICROBIA, INC. (US) 2006-08-17 WO disclosed
EP-0886637-A1 INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 1998-12-30 EP disclosed
EP-0886637-A4 1998-12-30 EP disclosed
US-H1729-H Method for preparing compounds employing solid phase synthesis and novel linker-resin BRISTOL-MYERS SQUIBB COMPANY (US) 1998-05-05 US disclosed
WO-1997043257-A1 INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD BRISTOL-MYERS SQUIBB COMPANY (US) 1997-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10023526-B2 Process for the preparation of lomitapide LIPA, LPAR4, CETP HDAC3 3105/4885HDAC4 2615/4885HDAC7 2532/4885
US-20200190018-A1 Process For The Preparation of Lomitapide LIPA, LPAR4, CETP HDAC3 3105/4885HDAC4 2615/4885HDAC7 2532/4885
US-10934251-B2 Process for the preparation of lomitapide LIPA, LPAR4, CETP HDAC3 3105/4885HDAC4 2615/4885HDAC7 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.